Roth Capital Resumes Savara (SVRA) at Neutral

Roth Capital analyst Jotin Marango resumes coverage on Savara (NASDAQ: SVRA) with a Neutral rating and a price target of $12.00.

The analyst comments "Savara is on track towards pivotal data in two different orphan pulmonary indications in 2019. However, in both cases, we see several “development leaps” between the prior supporting clinical data and the ongoing Phase 3 pivotal studies, which weaken our conviction in clean pivotal wins next year."

For an analyst ratings summary and ratings history on Savara click here. For more ratings news on Savara click here.

Shares of Savara closed at $11.14 yesterday.

You May Also Be Interested In

• Goldman Sachs Starts Lovisa Holdings Ltd (LOV:AU) at Neutral
• Lake Street Starts Vivani Medical, Inc. (VANI) at Buy
• Outdoor Holding (POWW) PT Raised to $2.75 at Roth/MKM, reiterates Top Pick